Earlier analyses demonstrated strong local tumor control, with nearly nine in 10 patients remaining free of recurrence at ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive ...

Laparoscopic and percutaneous approaches have similar short-term efficacy in treating renal tumors. Laparoscopic (LAP) and CT-guided percutaneous (PERC) cryoablation for renal tumors result in similar ...

ORLANDO -- Cryoablation without excision for low-risk, early-stage breast cancer may be an option for women over 60, 5-year follow-up results from the ICE3 trial showed. At a mean follow-up of 54.2 ...

IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...

IceCure Medical (ICCM) announced the completion of its last patients’ five-year follow up evaluation in its ICESECRET ...

Purchase funded by the Thomas Foundation following FDA marketing authorization of ProSense (R) in low-risk breast cancer and inclusion of cryoablation in proposed medical society guidelines ...

Percutaneous cryoablation may provide a safe and effective treatment option for patients with renal tumors, new findings suggest. David J. Breen, MD, and colleagues from University Hospitals of ...

CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...

PFA was noninferior to cryoablation for first recurrence of atrial tachyarrhythmia in patients with paroxysmal atrial fibrillation. Tissue-selective energy delivery and short application times offer ...